Implant Sciences Continues to Win ECAC Follow-on Orders as Austrian Airports Place Additional Orders for QS-B220s
WILMINGTON, Mass., Oct. 22, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has received a follow-on order for 16 additional QS-B220 Desktop Explosives Trace Detectors, for deployment to airports in Austria. Earlier this year, airports in Austria purchased and deployed 22 of Implant Sciences' QS-B220s for passenger and baggage checkpoint screening.
Over the past six months, Implant Sciences has announced a string of significant sales orders, after having successfully met the new European Civil Aviation Conference's (ECAC) standards for aviation screening of passengers and baggage. The QS-B220 was the first explosives trace detector to pass ECAC testing, which sets stringent standards for security equipment deployed across EU nations.
"Implant Sciences has experienced noteworthy success in the European market since the spring of 2015, leading to the most positive year in the company's history as manufacturer of explosives trace detectors," stated Dr. Bill McGann, CEO of Implant Sciences. "We are moving towards 2016 with a backlog of over $40 million, comprised of our ECAC and TSA orders. We have carefully planned for this rapid growth and scaled our production capability to allow us to meet the increased demand for our products."
"As the pioneer of non-rad IMS explosives trace detection, with thousands of units deployed around the world, we are pleased to see additional repeat customers emerging in the European aviation market," added Dr. Darryl Jones, Implant Sciences' Executive Vice President. "Our system's easy-to-use interface, low false alarm rate, and high performance continue to drive customers to choose our product."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 70 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint". All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; the risk that the Company may not be able to meet demand for its products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
Contact:
Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116
SOURCE Implant Sciences Corporation
Share this article